Oncolytics Biotech (ONCY) Other financing activities (2009 - 2023)
Oncolytics Biotech (ONCY) posted quarterly Other financing activities of $275450.8 for Q4 2023, up 486.15% quarter-over-quarter from $46993.6 in Q3 2023.
Oncolytics Biotech (ONCY) Other financing activities (2009 - 2023) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Other financing activities for 14 consecutive years, with $275450.8 the latest figure, recorded in Q4 2023.
- In Q4 2023, Other financing activities changed N/A year-over-year to $275450.8; the TTM figure through Dec 2024 stood at $322444.4 (changed 0.0% YoY), while the FY2025 annual figure was -$27000.0, down 157.45% from the prior year.
- Other financing activities rose to $275450.8 in Q4 2023 per ONCY's latest filing, from $46993.6 in the prior quarter.
- Across five years, Other financing activities topped out at $4.5 million in Q3 2019 and bottomed at -$1.1 million in Q4 2020.
- Historically, Other financing activities has averaged $470650.0 across 5 years, with a median of $46993.6 in 2023.
- Annual changes were most pronounced in 2019 — Other financing activities soared 5032.73% — and 2021, when it plunged 97.1%.
- Oncolytics Biotech's Other financing activities stood at $4.5 million in 2019, then plunged by 124.78% to -$1.1 million in 2020, then surged by 100.5% to $5596.2 in 2021, then soared by 69.29% to $9473.7 in 2022, then surged by 2807.53% to $275450.8 in 2023.
- Business Quant data shows ONCY's Other financing activities at $275450.8 in Q4 2023, $46993.6 in Q3 2023, and $9473.7 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 275,450.82 |
| Dec 31, 2023 | 275,450.82 |
| Sep 30, 2023 | 46,993.62 |
| Sep 30, 2023 | 46,993.62 |
| Mar 31, 2022 | 9,473.70 |
| Mar 31, 2022 | 9,473.70 |
| Dec 31, 2021 | 5,596.19 |
| Dec 31, 2021 | 5,596.19 |
| Sep 30, 2021 | 3,840.17 |
| Sep 30, 2021 | 3,840.17 |
| Jun 30, 2021 | 5,504.32 |
| Jun 30, 2021 | 5,504.32 |
| Mar 31, 2021 | 182,470.23 |
| Mar 31, 2021 | 182,470.23 |
| Dec 31, 2020 | -1.12 Mn |
| Dec 31, 2020 | -1.12 Mn |
| Jun 30, 2020 | 189,905.98 |
| Jun 30, 2020 | 189,905.98 |
| Mar 31, 2020 | 1.07 Mn |
| Mar 31, 2020 | 1.07 Mn |